navitoclax (ABT 263) / AbbVie  >>  Phase 2
Welcome,         Profile    Billing    Logout  

18 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
navitoclax (ABT 263) / AbbVie
NCT00918450: Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

Withdrawn
2b
150
US
ABT-263
Abbott, Genentech, Inc.
B-cell Chronic Lymphocytic Leukemia
12/12
 
NCT01087151 / 2009-012152-24: A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

Checkmark ICML 2013
Jun 2013 - Jun 2013: ICML 2013
Checkmark P2 data-ASH
Nov 2012 - Nov 2012: P2 data-ASH
Completed
2
118
US, Europe, RoW
ABT-263, rituximab
Genentech, Inc., AbbVie (prior sponsor, Abbott)
Chronic Lymphocytic Leukemia
06/12
06/12
NCT01557777 / 2012-000606-29: Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

Completed
2
17
US, Europe, RoW
Navitoclax, ABT-263
AbbVie (prior sponsor, Abbott)
Chronic Lymphocytic Leukemia
07/13
07/13
NAVIGATE, NCT01423539: A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Withdrawn
2
0
US
bendamustine, navitoclax, rituximab
Genentech, Inc., AbbVie (prior sponsor, Abbott)
Diffuse Large B-Cell Lymphoma
02/14
02/14
NCT01828476: Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Terminated
2
13
US
Abiraterone, ABT-263, Hydroxychloroquine
Rutgers, The State University of New Jersey, Rutgers Cancer Institute of New Jersey, National Cancer Institute (NCI), AbbVie
Prostate Cancer
02/16
03/16
MONAVI-1, NCT02591095 / 2015-000193-35: A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

Completed
2
47
Europe
ABT-263
Centre Francois Baclesse, ARCAGY/ GINECO GROUP, French Cancer Research Hospital Program
Platinum-resistant or Refractory Ovarian Cancer
04/17
03/19
REFINE, NCT03222609 / 2017-001398-17: A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Checkmark Data from P2 REFINE trial for myelofibrosis
Dec 2022 - Dec 2022: Data from P2 REFINE trial for myelofibrosis
Checkmark Data from P2 REFINE trial in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from P2 REFINE trial in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis at ASH 2022
Completed
2
191
Europe, Canada, Japan, US, RoW
Ruxolitinib, Jakafi, Navitoclax, ABT-263
AbbVie
Myelofibrosis (MF)
03/22
01/25
NCT06210750: Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Withdrawn
2
154
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Calaspargase Pegol, Asparaginase (Escherichia coli Isoenzyme II), Conjugate with alpha-(((2,5-Dioxo-1-pyrrolidinyl)oxy)carbonyl)-omega-methoxypoly(oxy-1,2-ethanediyl), Asparlas, Calaspargase Pegol-mknl, EZN-2285, SC-PEG E. Coli L-Asparaginase, Succinimidyl Carbonate Monomethoxypolyethylene Glycol E. coli L-Asparaginase, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin, Daunomycin, Daunorrubicina, DNR, Leukaemomycin C, Rubidomycin, Rubomycin C, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Echocardiography, EC, Lumbar Puncture, LP, Spinal Tap, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Nelarabine, 2-Amino-6-methoxypurine arabinoside, 506U78, Arranon, Compound 506U78, GW506U78, Pegaspargase, L-Asparaginase with Polyethylene Glycol, Oncaspar, Oncaspar-IV, PEG-Asparaginase, PEG-L-Asparaginase, PEG-L-Asparaginase (Enzon - Kyowa Hakko), PEGLA, Polyethylene Glycol L-Asparaginase, Polyethylene Glycol-L-Asparaginase, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Thioguanine, 2-Amino 6MP, 2-Amino-1,7-dihydro-6H-purine-6-thione, 2-Amino-6-mercaptopurine, 2-Amino-6-purinethiol, 2-Aminopurin-6-thiol, 2-Aminopurine-6(1H)-thione, 2-Aminopurine-6-thiol, 2-Aminopurine-6-thiol Hemihydrate, 2-Mercapto-6-aminopurine, 6-Amino-2-mercaptopurine, 6-Mercapto-2-aminopurine, 6-Mercaptoguanine, 6-TG, 6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI), BW 5071, Lanvis, Tabloid, Thioguanine Hemihydrate, Thioguanine Hydrate, Tioguanin, Tioguanine, Wellcome U3B, WR-1141, X 27, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vincristine, LCR, Leurocristine, VCR, Vincrystine, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
09/26
09/26
NCT05864742: Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Active, not recruiting
2
40
RoW
Ibrutinib, imbruvica, Venetoclax, Venclexta, Navitoclax, ABT-263, Rituximab, Rituxan
Peter MacCallum Cancer Centre, Australia
Mantle Cell Lymphoma Refractory
06/26
06/29
NCT00445198 / 2006-003298-28: A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

Checkmark P2 data (SCLC)
Apr 2012 - Apr 2012: P2 data (SCLC)
Checkmark P1 data (Solid tumor, SCLC)
Feb 2011 - Feb 2012: P1 data (Solid tumor, SCLC)
Completed
1/2
86
US, Canada, Europe
ABT-263
AbbVie (prior sponsor, Abbott), Genentech, Inc.
Small Cell Lung Cancer, Small Cell Lung Carcinoma
12/10
12/10
NCT00406809: A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Completed
1/2
81
Canada, US
ABT-263
AbbVie (prior sponsor, Abbott)
Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Peripheral T-cell Lymphoma
10/16
10/16
NCT01970956: Dabrafenib/Trametinib/Navitoclax In Braf Mutant Melanoma

Not yet recruiting
1/2
18
US
Navitoclax, ABT-263, Dabrafenib, GSK2118436, GSK2118436A (free base), Tafinlar, Trametinib, GSK1120212, JTP-74057, JTP-78296, JTP-75303, Mekinist
Massachusetts General Hospital, National Cancer Institute (NCI)
BRAF Mutant Melanoma, Solid Tumors
01/17
09/20
NCT03366103: Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

Terminated
1/2
15
US
Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Vistusertib, AZD 2014, AZD-2014, AZD2014
National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7, Stage IIIA Lung Small Cell Carcinoma AJCC v7, Stage IIIB Lung Small Cell Carcinoma AJCC v7, Stage IV Lung Small Cell Carcinoma AJCC v7, Unresectable Solid Neoplasm
07/21
09/22
NCT00481091 / 2007-002143-25: A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Completed
1/2
60
Europe, US, RoW
ABT-263, Navitoclax
AbbVie, Genentech, Inc.
Chronic Lymphocytic Leukemia
05/22
05/22
NCT02079740: Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
96
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
12/22
03/26
NCI-2013-02103, NCT01989585: Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Active, not recruiting
1/2
75
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography, Dabrafenib, BRAF Inhibitor GSK2118436, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A, Echocardiography Test, EC, Echocardiography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Pharmacological Study, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma
12/27
12/27
NCT05192889: Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Active, not recruiting
1/2
35
US
Venetoclax, Venclextra®, ABT-199, Navitoclax, ABT-263, Dexamethasone, Decadron®, Hexadrol®, Dexameth®, Vincristine, Vincristine sulfate, Oncovin®, Calaspargase Pegol, Asparlas, Dasatinib, Sprycel®, Cytarabine, Ara-C, Cytosar-U®, Blinatumomab, Blincyto®, Methotrexate, MTX, Trexall®, amethopterin, Mercaptopurine, 6-MP, Purinethol®, Cyclophosphamide, Cytoxan®, Etoposide, VP-16, Vepesid®, Leucovorin, Folinic acid, Intrathecal Triples, ITMHA, methotrexate/hydrocortisone/cytarabine, Pegaspargase, Oncaspar®, PEG-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Erwinase®, Radiation, Irradiation
St. Jude Children's Research Hospital, AbbVie
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
06/24
02/27
HEM-iSMART A, NCT05740449: HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Withdrawn
1/2
26
Europe
Decitabine, Venetoclax, Navitoclax, intrathecal chemotherapy
Princess Maxima Center for Pediatric Oncology, Innovative Therapies For Children with Cancer Consortium, IBFM, Fight Kids Cancer
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
10/29
10/29

Download Options